SCHEMBL2411379

SCHEMBL2411379

Cc1cc([N+](=O)[O-])c(F)cc1Oc1ccnc(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIN1 Q13526 2/20 0.39
▸ HSPB1 P04792 1/20 0.38
▸ MAPT P10636 6/20 0.37
▸ ALDH1A1 P00352 4/20 0.36
▸ GFER P55789 1/20 0.36
▸ LMNA P02545 6/20 0.36
▸ POLB P06746 3/20 0.36
▸ MEN1 O00255 3/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ TDP1 Q9NUW8 2/20 0.36
▸ THRB P10828 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ IDO1 P14902 1/20 0.36
▸ RECQL P46063 1/20 0.36
▸ TDO2 P48775 1/20 0.36
▸ BLM P54132 1/20 0.36
▸ CASP6 P55212 1/20 0.36
▸ HTT P42858 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL107560 0.89 MAPT (0.39) PIN1HSPB1MAPTALDH1A1LMNA
SCHEMBL30965188 0.89 MAPT (0.39) PIN1HSPB1MAPTALDH1A1LMNA
SCHEMBL16386609 0.89 LMNA (0.38) PIN1MAPTALDH1A1GFERLMNA
SCHEMBL137478 0.88 TDP1 (0.38) PIN1HSPB1MAPTALDH1A1LMNA
SCHEMBL16059862 0.85 MAPT (0.38) PIN1HSPB1MAPTALDH1A1LMNA
SCHEMBL16654904 0.80 MERTK (0.44) PIN1HSPB1MAPTALDH1A1LMNA
SCHEMBL24168282 0.79 PDE7A (0.45) HSPB1MAPTALDH1A1LMNAMEN1
SCHEMBL29414899 0.79 PDE7A (0.45) HSPB1MAPTALDH1A1LMNAMEN1
SCHEMBL15554319 0.78 MAPT (0.43) PIN1MAPTALDH1A1LMNAPOLB
SCHEMBL2413935 0.78 SCN9A (0.36) POLBKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2365752-B1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2014-09-24 — — EP disclosed
US-8486951-B2 Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2013-07-16 — — US disclosed
US-20130079362-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2013-03-28 — — US disclosed
US-8278331-B2 N-acyl ureas exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2012-10-02 — — US disclosed
CN-102256493-A Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS LLC 2011-11-23 — — CN disclosed
EP-2365752-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES Deciphera Pharmaceuticals, Llc (US) 2011-09-21 — — EP disclosed
US-20100120806-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC 2010-05-13 — — US disclosed
WO-2010051373-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2010-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079362-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES KIT, PDGFRA, PDGFRB PIN1 3182/4885HSPB1 1343/4885MAPT 3045/4885
US-20100120806-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES KIT, PDGFRA, PDGFRB PIN1 3399/4885HSPB1 1193/4885MAPT 3019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback